Navidea Biopharmaceuticals Aktie [WKN DE: A2PH4J / ISIN: US63937X2027]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Navidea Biopharmaceuticals Inc Registered Shs

12.05.22		Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results (Businesswire)
05.05.22		Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update (Businesswire)
20.04.22		Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets (Businesswire)
19.04.22		Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis (Businesswire)
18.04.22		Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India (Businesswire)
12.04.22		Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series (Businesswire)
12.04.22		Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American (Businesswire)
23.03.22		Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results (Businesswire)
07.02.22		Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma (Businesswire)
03.02.22		Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American (Businesswire)
16.12.21		Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis (Businesswire)
16.12.21		Pre-market Movers: CALT, SABS, IRNT, CTK, VALN… (RTTNews)
15.12.21		Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program (Businesswire)
15.12.21		Navidea Biopharmaceuticals Terminates Stock Purchase Agreement (Businesswire)
13.12.21		Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis (Businesswire)
09.12.21		Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition (Businesswire)
15.07.21		Navidea Biopharma : FDA Meeting On Rheumatoid Arthritis To Take Place On Sept 1 (RTTNews)
24.06.21		Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty (Businesswire)
19.05.21		Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections (Businesswire)
11.05.21		Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results (Businesswire)
05.05.21		Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition (Businesswire)
04.05.21		Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update (Businesswire)
15.04.21		Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium (Businesswire)
24.03.21		Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
17.03.21		Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
02.03.21		Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference (Businesswire)
02.03.21		Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor (Businesswire)
08.02.21		Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis (Businesswire)
07.01.21		Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021 (Businesswire)
28.12.20		Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter (Businesswire)
13.11.20		Pre-market Movers In Healthcare Sector: UROV, NAVB, BNGO, DFFN, KROS… (RTTNews)
13.11.20		AZN's Repurposed COVID-19 Drug Fails, NAVB On Watch, CVAC Rallies On Storage Advantage Of CVnCoV (RTTNews)
12.11.20		Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results (Businesswire)
12.11.20		Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis (Businesswire)
05.11.20		Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
22.10.20		Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable (Businesswire)
09.10.20		Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting (Businesswire)
28.09.20		Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange (Businesswire)
08.09.20		Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
02.09.20		Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation (Businesswire)
24.08.20		Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference (Businesswire)
13.08.20		Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results (Businesswire)
10.08.20		Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership (Businesswire)
10.08.20		Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma (Businesswire)
06.08.20		Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
22.05.20		Stock Alert: Navidea Biopharma Shares Up 75% In Late Trade (RTTNews)
21.05.20		Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis (Businesswire)
14.05.20		Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results (Businesswire)
11.05.20		Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® (Businesswire)
07.05.20		Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Strategische Bitcoin-Reserve: USA erwägen milliardenschweren Bitcoin-Kauf

Novo Nordisk-Aktien und Eli Lilly-Papiere crashen: Ist der Erfolgstraum ausgträumt?

VW-Aktie unter Druck: Flächendeckender Streik bei Volkswagen - Tausende Jobs in Österreich abhänging

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	03.12.2024 04:26
Kaufwert:	EUR
	Hinzufügen Speichern